Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?

Matti Aapro · Jeffrey Crawford · Didier Kamioner

Received: 4 September 2009 / Accepted: 7 January 2010 / Published online: 27 February 2010 © The Author(s) 2010. This article is published with open access at Springerlink.com

Abstract Updated international guidelines published in 2006 have broadened the scope for the use of granulocyte colony-stimulating factor (G-CSF) in supporting delivery of myelosuppressive chemotherapy. G-CSF prophylaxis is now recommended when the overall risk of febrile neutropenia (FN) due to regimen and individual patient factors is ≥20%, for supporting dose-dense and dose-intensive chemotherapy and to help maintain dose density where dose reductions have been shown to compromise outcomes. Indeed, there is now a large body of evidence for the efficacy of G-CSFs in supporting dose-dense chemotherapy. Predictive tools that can help target those patients who are most at risk of FN are now becoming available. Recent analyses have shown that, by reducing the risk of FN and chemotherapy dose delays and reductions, G-CSF prophylaxis can potentially enhance survival benefits in patients receiving chemotherapy in curative settings. Accumulating data from ‘real-world’ clinical practice settings indicate that patients often receive abbreviated courses of daily G-CSF and consequently obtain a reduced level of FN protection. A single dose of PEGylated G-CSF (pegfilgrastim) may provide a more effective, as well as a more convenient, alternative to daily G-CSF. Prospective studies are needed to validate the importance of delivering the full dose intensity of standard chemotherapy regimens, with G-CSF support where appropriate, across a range of settings. These studies should also incorporate prospective evaluation of risk stratification for neutropenia and its complications.

Keywords Cancer treatment · Colony-stimulating factors · Neutropenia · Guidelines

Introduction

Neutropenia is a major dose-limiting toxicity of myelosuppressive chemotherapy that predisposes patients to serious infections. Febrile neutropenia (FN), generally defined as fever (single oral temperature ≥38.3°C or ≥38.0°C for >1 h) with grade 3/4 neutropenia (absolute neutrophil count [ANC] <1.0 or <0.5×10⁹/l), is associated with substantial morbidity, escalation of costs and mortality risk [1–5]. Severe neutropenia and FN episodes are also major drivers of chemotherapy dose delays and reductions [6–8], which have been shown to compromise survival outcomes in various curative settings [7, 9–13].

Prophylaxis with recombinant granulocyte colony-stimulating factors (G-CSFs) reduces the severity and duration of chemotherapy-induced neutropenia and the consequent risk of FN [14, 15] and is playing an increasingly broad role in supporting the delivery of myelosuppressive chemotherapy [16–18].

The aim of this article is to review recent developments in the use of G-CSFs in this setting. A literature search was conducted using the search terms “granulocyte colony-stimulating factor”, “leukaemia”, “lymphoma” and “solid
tumours”. Additional studies were identified by hand-searching reference lists of retrieved papers. Conference websites were searched for recent reports (2006 onwards) not covered by published literature, using the search terms “G-CSF”, “granulocyte colony-stimulating factor”, “neutropenia”, “filgrastim”, “lenograstim” and “pegfilgrastim”.

Who should receive G-CSFs?

Official guidelines from Europe and the USA now agree that primary G-CSF prophylaxis should be given when the overall risk of FN due to regimen and patient factors is ≥20% [16–20]. Prior to 2006, primary G-CSF prophylaxis was recommended for chemotherapy regimens associated with a relatively high FN risk of 40% [21]. However, data showed that clinical benefit was obtained at a much lower threshold of risk [22, 23], and the importance of individual patient risk factors was also recognised [16, 17].

Regimens with an overall risk of FN of ≥20% include anthracycline/taxane regimens that are used for treatment of breast cancer, cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP)-like regimens used for non-Hodgkin’s lymphoma (NHL) [16, 18] and the docetaxel, cisplatin and 5-fluorouracil (DCF/TPF) regimen used for gastric [24] and head and neck [25, 26] cancer.

Immunomodulatory derivatives of thalidomide such as lenalidomide have shown promise for the treatment of myeloma [27, 28]. These agents appear to induce neutropenia by transiently blocking the maturation of granulocytes, rather than via stem cell toxicity, suggesting that this might be prevented by G-CSF administration [29]. Further work is required to define the risk of FN with these agents.

For regimens that are associated with a 10–20% risk of FN, individual patient factors must also be considered when determining the need for G-CSF support (Fig. 1). There is high-level evidence for older age, advanced-disease stage and FN occurrence in a first or previous chemotherapy cycle as risk factors for FN [16]. Other factors that have been reported to increase risk include the presence of comorbidities and poor performance/nutritional status [16–18]. As age >65 years is consistently shown to be associated with increased FN risk, G-CSF prophylaxis should be considered for supporting chemotherapy delivery in all elderly patients receiving myelotoxic chemotherapy [30].

Historically, it was common practice to reduce the chemotherapy dose instead of administering G-CSF in at-risk patients, but this strategy risks obtaining suboptimal results. Rather, G-CSF use should be guided by the intent of treatment (i.e., whether curative or for prolonging survival as opposed to palliative). If reduction in chemotherapy dose intensity or density is associated with poor prognosis or where dose-dense or dose-intensive chemotherapy regimens have survival benefits, G-CSF prophylaxis should be used. Where this is not crucial, use of a less myelosuppressive chemotherapy regimen or dose/schedule modification can be considered [16].

G-CSF to support chemotherapy: new data

Anthracycline/taxane regimens, particularly doxorubicin-containing regimens, have become a standard of care in breast cancer. Docetaxel, doxorubicin and cyclophosphamide (TAC) is a combination regimen that has high efficacy in the adjuvant setting, reducing the risk of death by 30% compared to fluorouracil, doxorubicin and cyclophosphamide (FAC) [31]. While TAC is associated with a relatively high risk of FN (>20%) and other toxicities, delivery is feasible with effective growth factor support [32, 33]. As well as reducing the risk of FN, G-CSF prophylaxis has also been reported to attenuate non-haematological toxicities such as asthenia/anorexia, stomatitis/mucositis and diarrhoea in TAC recipients [32, 33]. It is unknown whether this is a direct protective effect or related to decreased cytokine release via the reduced risk of infection.

Elderly patients have often not been considered as candidates for full-dose aggressive chemotherapy, but there is a growing body of evidence to show that, with adequate G-CSF support, delivery of myelosuppressive chemotherapy [34–37], including taxane-containing (neo)adjuvant regimens [36, 37] and dose-dense CHOP (discussed in a later section), is feasible in this population.

Recent prospective data from a large community-based study have confirmed previous observations that FN is most common in the first cycle of chemotherapy [38], and this underlines the need to start G-CSF from the first cycle in appropriate patients. Prophylactic use of G-CSF (pegfilgrastim) from cycle 1 was shown to reduce the incidence of FN by approximately 60% compared with reactive use (initiated after cycle 1 at the physician’s discretion) in elderly patients (aged ≥65 years; n=852) receiving a range of mild to moderately myelosuppressive chemotherapy regimens for solid tumours (lung, breast or ovarian cancer) or NHL [35]. Among those with solid tumours, FN occurred in 10% (95% confidence interval [CI] 7–14%) of the reactive-use group versus 4% (95% CI 2–6%) of the pegfilgrastim primary prophylaxis group (p=0.001). Among NHL patients, FN occurred in 37% (95% CI 26–49%) of the reactive-use versus 15% (95% CI 8–25%) of the pegfilgrastim primary prophylaxis group (p=0.004).
Development of risk models

A number of groups have been developing predictive models to identify patients at increased risk of severe myelosuppression, low dose intensity and/or FN during chemotherapy for breast cancer [8, 39–42], NHL [8, 43, 44] or various cancer types [45–47]. The models are based on traditional risk factors such as age, gender, bodyweight and performance status, as well as disease type and stage, haematology/clinical chemistry, chemotherapy, whether G-CSF was given and a previous history of FN (Table 1). A number of these have been validated retrospectively using existing patient datasets [43, 46].

Jenkins et al. demonstrated that patients receiving adjuvant 5-fluorouracil, epirubicin, cyclophosphamide (FEC) chemotherapy for breast cancer could be divided into five risk groups, in which the risk for neutropenic events ranged from 18% to 52%, the risk of receiving suboptimal (<85%) chemotherapy dose intensity from 9% to 36% and the risk of FN from 4% to 21%, based only on their pretreatment absolute neutrophil and lymphocyte counts [40].

![Fig. 1 Algorithm for determining whether granulocyte colony-stimulating factor (G-CSF) prophylaxis is indicated in patients undergoing chemotherapy](image-url)

> FN febrile neutropenia. Adapted from (a) Aapro et al. [16], with permission from Elsevier. Incorporating data from (b) Smith TJ et al. [17]

Table 1 Risk models for febrile neutropenia (FN) or severe haemotoxicity in patients receiving myelosuppressive chemotherapy

| Regimen/disease | Risk assessed by model | Basic characteristics | Disease characteristics | Haematology/clinical chemistry | Treatment factors | History |
|-----------------|------------------------|-----------------------|------------------------|-------------------------------|-------------------|---------|
| Doxorubicin or liposomal doxorubicin/metastatic breast cancer | Neutropenic complications<sup>a</sup> | Age ≥ 59 years; performance status | Neutrophils ≤ 2 × 10<sup>9</sup>/l in previous cycle | Whether first cycle, doxorubicin or liposomal doxorubicin | Planned cyclophosphamide, cytarabine, etoposide dose; G-CSF use | Previous chemotherapy; recent infection |
| Various/NHL | FN | Age; bodyweight | Baseline albumin | Planned cyclophosphamide, cytarabine, etoposide dose; G-CSF use | Planned cyclophosphamide, cytarabine, etoposide dose; G-CSF use | First cycle FN |
| CHOP-like regimens/ NHL | Neutropenia | Gender; bodyweight; performance status | Baseline haemoglobin; leucocytes; thrombocytes; GGT; LDH | Chemotherapy cycle length; etoposide use; vincristine dosage; G-CSF use | Various chemotherapy agents; prior chemotherapy; immunosuppressive agents; G-CSF use |
| Various | Older age | Disease stage; bone marrow involvement | WBC; abnormal hepatic or renal function | Various chemotherapy agents; prior chemotherapy; immunosuppressive agents; G-CSF use |

<sup>a</sup> Absolute neutrophil count ≤ 1.5 × 10<sup>9</sup> cells/l, FN or neutropenia with a documented infection.

*CHOP* cyclophosphamide, doxorubicin, vincristine, prednisone, *GGT* gamma glutamyltransferase, *LDH* lactate dehydrogenase, *NHL* non-Hodgkin’s lymphoma
Ziepert et al. [43] have developed a validated web-based tool for predicting the grade of haematological toxicity (leucopenia, thrombocytopenia and anaemia, but not specifically neutropenia) in lymphoma patients treated with CHOP-like therapies in clinical practice (www.toxcalculator.com). It was calculated that use of these models, which again stratify patients into five risk groups, could potentially spare intensive prophylactic strategies in 10–38% or 16–38% of patients, depending on whether cycle 1 data are available. Pettengell et al. [44] found that their model had high sensitivity (81%) and specificity (80%) for predicting cycle 1 FN in patients with NHL, with a 28% positive and 98% negative predictive value.

Lyman et al. [46] developed a predictive model for neutropenic events that they retrospectively validated, using data from 4,458 patients treated for various cancers in clinical practice. The model demonstrated good discrimination, predicting cycle 1 neutropenic events in 34% of high-risk and 4% of low-risk patients, with a sensitivity and specificity of 90% and 59%, respectively. G-CSF primary prophylaxis was confirmed as a protective factor, and almost two thirds of patients in the validation dataset who were classified as high risk but did not receive primary G-CSF prophylaxis subsequently received secondary G-CSF prophylaxis in later cycles.

Once prospectively validated, such models will be a valuable resource for helping to target G-CSF support.

Dose-dense/intense treatment

Shortening the time interval between chemotherapy cycles from the conventional 3-week, to a 2-week, cycle—dose densification—is thought to maximise tumour cell kill and minimise regrowth between cycles [48, 49]. Moreover, completion of chemotherapy within a shorter time frame may allow patients to resume their normal activities sooner. Earlier landmark studies with anthracycline/taxane regimens in breast cancer [50], CHOP-like regimens in aggressive lymphomas [51, 52] and doxorubicin/cyclophosphamide/doxorubicin, etoposide, vincristine, bleomycin, procarbazine and prednisone at full dose, on time in patients with Hodgkin’s lymphoma [60].

In the breast cancer setting, several recent reports have documented the efficacy of pegfilgrastim in supporting delivery of dose-dense anthracycline/taxane regimens, including docetaxel followed by epirubicin/cyclophosphamide (T→EC) or the reverse sequence (EC→T) [61] and fluorouracil, epirubicin, cyclophosphamide→docetaxel (FEC→Doc) [62], as well as FEC alone [63]. Dose-dense sequential doxorubicin plus cyclophosphamide followed by paclitaxel (AC→T) was well tolerated when administered with pegfilgrastim and additional red cell support (darbepoetin alfa) in patients with haemoglobin ≤12 g/dl, with few chemotherapy dose reductions or episodes of FN (<2% of patients) [64].

In patients with SCLC, full-dose, on-schedule, dose-dense ACE chemotherapy was found to be feasible with pegfilgrastim support [65].

Use of G-CSF has also allowed investigation of higher chemotherapy dosages, but the benefits of dose escalation alone are presently unclear, suggesting that currently used dosages may already be optimal in most settings, provided that they can be delivered safely. For instance, significant dose escalations of cyclophosphamide, doxorubicin, vincristine, prednisone and etoposide (CHOEP) were possible with G-CSF support (filgrastim or lenograstim) in young patients with lymphoma [66], but this strategy did not enhance clinical benefits compared with standard CHOEP-21 [67].

Impact of G-CSF on chemotherapy delivery and survival outcomes

Recent data from a large US survey (41,779 patients with FN treated at 115 medical centres) have highlighted the mortality risk associated with FN. Overall, in-hospital mortality was 9.5% and increased with the number of comorbidities; 2.6% in those without any major comorbidity, 10.3% in those with one major comorbidity and >21% in those with more than one major comorbidity [3].

There are now much data to show that reduced chemotherapy dose intensity due to delays and dose reductions can potentially compromise survival outcomes in patients receiving curative treatment [7, 9–13, 68]. Even moderate reductions can negatively impact survival. For instance, in NHL patients treated with CHOP-like chemotherapy (n=210), failure to achieve a relative dose intensity
(RDI; the ratio of actual dose to planned dose of chemotherapy over the same time interval) of >90% resulted in significantly shorter mean overall survival (2.24 vs. 5.38 years; \( p=0.002 \)) [7].

The prospective Impact of Neutropenia in Chemotherapy-European observational study in breast cancer (\( n=444 \)) and lymphoma (\( n=305 \)) patients undergoing chemotherapy found that first-cycle FN, age \( \geq 65 \) years and Eastern Cooperative Oncology Group (ECOG) performance score \( >1 \) were associated with low RDI in both groups of patients, with G-CSF primary prophylaxis protecting against low RDI in the lymphoma patients [8]. A meta-analysis of ten studies that reported RDI as an outcome found that average RDI in patients treated for solid tumours or lymphoma ranged from 91.0% to 99.0% (mean 95.1%) in patients who received G-CSF, compared with only 71.0 to 95.0% (mean 86.7%) in those who did not [69].

There is now a growing body of evidence that improved chemotherapy delivery and reduction in FN with G-CSF [8, 69] may translate into better survival outcomes. Three meta-analyses of randomised studies comparing prophylactic G-CSF or granulocyte-macrophage colony-stimulating factor (GM-CSF) with placebo or no treatment have been conducted recently [69–71].

A meta-analysis of 17 studies compared primary prophylactic G-CSF (filgrastim, lenograstim or pegfilgrastim) with placebo or no treatment in 3,493 patients treated for solid tumours or lymphoma. In addition to improving RDI, G-CSF reduced the risk of infection-related mortality by 45% (1.5% vs. 2.8%; relative risk [RR] 0.55, 95% CI 0.33–0.90; \( p=0.018 \)) and early mortality (all-cause, during chemotherapy) by 40% (3.4% vs. 5.7%; RR 0.60, 95% CI 0.43–0.83; \( p=0.002 \); Fig. 2). As the patient populations in the studies included in this analysis tended to be relatively young and fit, it is possible that greater benefit of G-CSF might be seen in older populations [69].

However, a meta-analysis of 148 studies in a broad range of settings, including adults and children with cancer or undergoing stem cell transplantation, found prophylactic G-CSF or GM-CSF to have little or no effect on early mortality (7.6% vs. 8.0% of patients) or infection-related mortality (3.1% vs. 3.8%) versus placebo/no treatment [70]. Nevertheless, G(M)-CSF did reduce the risk of documented infections (median 38.9% vs. 43.1%; rate ratio 0.85, 95% CI 0.79–0.92) and microbiologically documented infections (median rate 23.5% vs. 28.6%; rate ratio 0.86, 95% CI 0.77–0.96) [70]. Similarly, a recent Cochrane database review of 13 trials in patients treated for lymphoma (\( n=2,607 \)) did not find any benefit of G-CSF or GM-CSF on overall survival (HR 0.97, 95% CI 0.87–1.09), freedom from treatment failure (HR 1.11, 95% CI 0.91–1.35), complete response (RR 1.03, 95% CI 0.95–1.10) or infection-related mortality (RR 0.93, 95% CI 0.51–1.71) [71].

The reasons for the differences between results of these three meta-analyses are not clear but probably relate to differences in individual study methodology and endpoints, as well as criteria for inclusion of studies. Both analyses that failed to show an effect of CSFs on mortality endpoints included studies that used GM-CSF (sargramostim or molgramostim) [70, 71], whereas the meta-analysis that demonstrated a survival benefit was restricted to studies of G-CSF [69]. It is thought that GM-CSF may be less effective than G-CSF in reducing FN and fever [72], and its use has been discontinued in Europe. In the USA, GM-CSF is not FDA-approved as an adjunct to standard myelosuppressive chemotherapy regimens in patients with solid tumours and lymphoma and has limited off-label use in this setting. Indeed, 61 of the 148 studies included in the Sung analysis used GM-CSF [70]. This analysis included transplant patients receiving high-dose chemotherapy, a different scenario from use of CSFs to support standard-dose chemotherapy. Moreover, only the Kuderer analysis [69] was restricted to trials in which daily CSFs were to be given continuously until neutrophil recovery.

Nevertheless, all three meta-analyses confirmed a substantial FN risk reduction in patients receiving G-CSF/GM-CSF support [69–71]. For instance, Kuderer et al. found that FN was reduced by 46% (22.4% vs. 39.5%; RR 0.54, 95% CI 0.43–0.67; \( p<0.001 \)) [69].

Exploratory data from a prospective observational study conducted at 115 US practices (\( n=4,458 \) patients) showed that pegfilgrastim significantly improved survival endpoints in patients with comorbidities who were receiving chemotherapy [73]. Of these patients, 41% were aged \( >65 \) years, 46% had ECOG performance score \( >1 \) and 38% had stage 4 disease. Patients receiving primary pegfilgrastim prophylaxis (\( n=620 \)) had better progression-free survival than those who did not, even after adjustment for other significant covariates. This study was not randomised.

![Fig. 2](image-url)
which limits firm conclusions, but these results are consistent with the G-CSF meta-analysis [69].

**Are the G-CSFs different?**

The non-PEGylated G-CSFs, standard G-CSF (filgrastim) and glycosylated G-CSF (lenograstim) appear to be broadly comparable in efficacy [16]. However, a growing body of evidence suggests that pegfilgrastim—a PEGylated formulation of filgrastim with neutrophil-regulated pharmacokinetics that is given as a single dose once per cycle [57, 74]—is more effective than filgrastim. A meta-analysis of five studies in a total of 617 patients treated for breast cancer or lymphoma showed that a single dose of pegfilgrastim was significantly more effective than 10–14 days of filgrastim in reducing FN (RR 0.64, 95% CI 0.43–0.97) [75]. Data from the larger meta-analysis by Kuderer et al. [69] also suggest that pegfilgrastim was more effective than either lenograstim or filgrastim, although it must be noted that the pegfilgrastim data came from a single study (Fig. 3). These findings might reflect the sustained stimulation of bone marrow by pegfilgrastim throughout the period of neutropenia.

Moreover, the way that filgrastim is administered in real-world clinical practice (and some clinical trials) may compromise its efficacy. It should be given daily, until ANC returns to the normal range; data from registrational trials indicate that this requires approximately 9–14 injections per chemotherapy cycle [14, 76]. However, it is common practice to administer fewer doses than this and/or to start treatment relatively late after chemotherapy [77–79]. Several analyses have shown that, when used in this manner, filgrastim may provide suboptimal protection against FN [33, 78, 79]. For instance, the Gepartrio study evaluated four different supportive regimens in consecutive cohorts of patients (n=1,256 total) receiving adjuvant TAC for breast cancer. FN occurred in 18% of patients who received an abbreviated course of daily G-CSF administered from days 5 to 10. However, a single dose of pegfilgrastim on day 2 reduced the incidence of FN to 7%; if ciprofloxacin was also incorporated into the prophylactic regimen, the risk was reduced to 5% (Fig. 4) [33].

An integrated analysis of data from 2,282 breast cancer patients compared pegfilgrastim primary prophylaxis with current-practice neutropenia management (a: no G-CSF or b: any G-CSF use other than protocol-specified pegfilgrastim

---

**Fig. 3** Efficacy of different granulocyte colony-stimulating factors in preventing infection-related mortality, early mortality and febrile neutropenia in 3,493 patients treated with chemotherapy for solid tumours or lymphoma. Forest plot of data from a meta-analysis of 17 randomised controlled studies comparing G-CSF primary prophylaxis with placebo or no treatment [69]
A retrospective US survey [77] of patients (n=6,148) treated in 99 community oncology practices for various cancers also found that FN was more common in those who received filgrastim (6.5%) than in those who received pegfilgrastim (4.7%) [adjusted OR 1.41, 95% CI 1.02–1.96; p=0.040]. However, whereas pegfilgrastim was administered within approximately 2 days after chemotherapy, filgrastim was started much later (mean >7 days and >5 days after chemotherapy in first and subsequent cycles, respectively), suggesting that filgrastim was used reactively instead of proactively. A similar analysis found that in community-based patients receiving various chemotherapy regimens (total of 15,763 cycles), the risk of hospitalisation was approximately 30% lower with pegfilgrastim support than with daily G-CSF [81].

Alternative versions of many innovative biopharmaceuticals, including G-CSF [82], are being developed. These “biosimilars” will not be identical to the corresponding original products because of differing protein sources and difficulties in replicating the complex proprietary manufacturing processes involved. While biosimilars may cost less, it is possible that small differences in biochemical and biophysical characteristics might translate into differences in potency and immunogenic potential [83].

**Tolerability issues**

**Bone pain**

Bone or musculoskeletal pain is a characteristic adverse event associated with G-CSF treatment. This is generally mild to moderate and can be managed with standard analgesics [84-86]. A large meta-analysis [69] found that bone or musculoskeletal pain was reported in approximately 20% of patients who received G-CSFs compared with approximately 10% of controls (RR 4.023, 95% CI 2.156–7.52; p<0.0001). Arthralgia is also an adverse effect of taxane chemotherapy [87], which is often administered with G-CSF support. Filgrastim and pegfilgrastim were associated with similar incidences of bone pain in another large analysis (RR 0.95, 95% CI 0.76–1.19) [75]. Although administering a lower-than-recommended dose of G-CSF (pegfilgrastim) was reported to be successful in reducing bone pain [88], this strategy obviously risks achieving suboptimal protection against FN [89], and it is at yet unclear whether bone pain is dose-related.

**Other short-term adverse events**

A proportion of patients may experience leucocytosis (white blood cell count >100×10^9/l) after receiving G-CSFs [64, 84, 90]. At ANC recovery, pegfilgrastim

![Fig. 4 Comparison of febrile neutropenia and grade 4 neutropenia incidence per patient and per cycle in patients receiving TAC chemotherapy for early breast cancer, supported by different primary prophylactic regimens: ciprofloxacin 500 mg orally twice daily on days 5–14 (n=253 patients), daily granulocyte colony-stimulating factor (G-CSF; filgrastim 5 µg/kg per day or lenograstim 150 µg/m^2 per day) on days 5–10 (n=374), pegfilgrastim (PEG) 6 mg on day 2 (n=303) or pegfilgrastim plus ciprofloxacin (PEG+CIP; n=314) [33]. *p<0.01, **p<0.001 versus CIP; †p<0.01, ††p<0.001 versus daily G-CSF. Reprinted from von Minckwitz et al. [33]. By permission of Oxford Journals/European Society for Medical Oncology]
clearance increases, resulting in a rapid decrease in serum concentrations. This resulted in less “overshoot” of ANC post-nadir compared with daily filgrastim [91]. Pegfilgrastim concentrations are negligible by day 12 and therefore unlikely to overstimulate neutrophil production [92].

G-CSFs can induce elevation of cancer antigen 15-3, a circulating marker of secreted products of the polymorphic MUC1 gene used for monitoring breast cancers, in breast cancer patients [93–96]. Physicians should be aware of the potential for this “false-positive” effect, which may occur via an increase in neutrophil counts or induction of MUC1 antigen [95]. There is no evidence that this is due to tumour stimulation.

Secondary malignancies

On the basis of retrospective data, it has been suggested that G-CSF/GM-CSF use might lead to a small increase in the risk of secondary malignancies. In patients treated with adjuvant chemotherapy for breast cancer, acute myeloid leukaemia or myelodysplastic syndrome (AML/MDS) occurred in 1.77% of those who had received G-CSF or GM-CSF (n=906) compared with 1.04% of those who had not (n=4,604; HR 2.14, 95% CI 1.12–9.52) [97]. However, as acknowledged by the investigators, anthracyclines and cyclophosphamide may increase the risk of second malignancies in a dose-related manner [98–100]; administration of G-CSF may have allowed higher chemotherapy doses to be delivered, thereby confounding the analysis. Moreover, data from other studies, including a very large observational study (n=64,715) [100], have not indicated an increased risk of secondary AML/MDS with G-CSF use [50, 100, 101].

A recent meta-analysis found that although intensified chemotherapy with G-CSF support slightly increased the risk of second malignancies compared with standard chemotherapy without G-CSF, this was more than offset by the survival benefits [102]. Thus, the overall risk/benefit ratio continues to favour G-CSF use [103], as it facilitates chemotherapy delivery and prevents life-threatening FN.

Clinical implications of new data

Guidelines published from 2006 onwards have broadened the scope of G-CSF use for supporting chemotherapy delivery. There is now a large body of evidence for the efficacy of pegfilgrastim, as well as filgrastim, in supporting dose-dense chemotherapy and facilitating delivery of the full dose on time. Importantly, recent data have provided further (albeit indirect) evidence that appropriate primary G-CSF prophylaxis can potentially confer survival benefits in patients receiving chemotherapy in the curative setting.

FN risk should be assessed on an individual patient basis, taking into account the regimen, patient- and disease-related factors and treatment intent. Predictive tools that will help clinicians to identify which patients are most likely to benefit from G-CSF prophylaxis are now starting to become available, and these will allow more efficient targeting of patients at high risk.

Several studies have documented the considerable cost burden of FN in patients receiving chemotherapy [1, 3]. An analysis in >40,000 US patients found that, on average, an FN episode resulted in a median hospital stay of 6 days and a median cost of $8,376, with 35% of patients being hospitalised for at least 10 days [3]. Smaller studies from various western European countries have provided estimates of the average charge for FN-related hospitalisation ranging from €2,619 in Spain to €4,931 in France [4, 104, 105]. These findings highlight the need to implement official guidelines for preventing FN. A number of economic analyses have indicated that the costs of G-CSFs can be at least partially offset by reduction of FN and its associated costs [106–108]. It should be noted that results of cost-effectiveness studies are dependent on the costs considered by each study, and such costs may differ between countries.

It is important that G-CSFs are used according to recommendations in order to gain the maximum benefit. In real-world clinical practice settings, patients often receive abbreviated courses of daily G-CSF treatment and this can reduce the level of FN protection obtained. Use of a single dose of pegfilgrastim per cycle in appropriate patients assures the delivery of adequate CSF support, providing a more convenient and potentially more effective strategy for assisting neutrophil recovery.

Prospective studies are needed to validate the importance of delivering the full dose intensity of standard chemotherapy regimens, integrated with G-CSF support where appropriate, across a range of tumour types. This will allow better quantification of the impact of both chemotherapy dose and supportive care in improving outcomes in cancer patients. These studies should also incorporate prospective evaluation of risk stratification for neutropenia and its complications, so that the use of both chemotherapy and G-CSFs can be optimised in the most cost-effective way.

Acknowledgement Writing support (drafting, literature searching and co-ordination) for this manuscript was provided by Julia Balfour, Consultant Medical Writer, Kilconquhar, Scotland, with funding from Amgen (Europe), GmbH, Dammstrasse 23, 6301 Zug, Switzerland. Scientific staff at Amgen reviewed the manuscript and provided comments.

Author Contributions and Disclosures

The concept for the review was developed by MA and data collection directed by all three authors. The manuscript was drafted by JB in conjunction with MA and subsequently revised by JC and DK. The final version was approved by all three authors.
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

1. Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT (2005) Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103:1916–1924
2. Courtney DM, Aldeen AZ, Gorman SM, Handler JA, Trifillo SM, Parada JP, Yarnold PR, Bennett CL (2007) Cancer-associated neutropenic fever: clinical outcome and economic costs of emergency department care. Oncologist 12:1019–1026
3. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258–2266
4. Mayordomo JI, Castellanos J, Pernas S, Ruiz-Borrego M, Velasco A, Frau A, Lamas MJ, Lara N, Gasquet J, Sánchez J (2006) Cost analysis of febrile neutropenia management of breast cancer patients in clinical practice in Spain. Ann Oncol 17 (Suppl 9):ix190–ix195, Abstract 617P
5. Elting LS, Lu C, Escalante CP, Giordano SH, Trent JC, Cooksley C, Aivritscher EB, Shih YC, Ensor J, Bekele BN, Gralla RJ, Talcott JA, Rolston K (2008) Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 26:606–611
6. Link BK, Budd GT, Scott S, Dickman E, Paul D, Lawless G, Lee MW, Fridman M, Ford J, Carter WB (2001) Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care. Cancer 92:1354–1367
7. Bosly A, Bron D, Van Hoof A, De Bock R, Berneman Z, Ferrant A, Kaufman L, Dauwe M, Verhoef G (2007) Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 87:277–283
8. Pettengell R, Schwenklenks M, Leonard R, Bosly A, Paridaens R, Costenla M, Szucs TD, Jackisch C (2008) Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer 16:1299–1309
9. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 332:901–906
10. Lee KW, Kim DY, Yun T, Kim DW, Kim TY, Yoon SS, Heo DS, Bang YJ, Park S, Kim BK, Kim NK (2003) Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage. Cancer 98:2651–2656
11. Kwak LW, Halpem J, Olshen RA, Hooming SJ (1990) Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 8:963–977
12. Chirivel I, Barriojo B, Insa A, Perez-Fidalgo A, Magro A, Rosello S, Garcia-Garre E, Martin P, Bosch A, Lluch A (2009) Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat 114:479–484
13. Pettengell R, Schwenklenks M, Bosly A (2008) Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Ann Hematol 87:429–430
14. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G et al (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in lymphoma patients with small-cell lung cancer. N Engl J Med 325:164–170
15. Crawford J (2002) Neutrophil growth factors. Curr Hematol Rep 1:95–102
16. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42:2433–2453
17. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo M, Wade JC, Walewski J, Winn RJ, Wozniak AJ, Wolff AC (2006) 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187–3205
18. National Comprehensive Cancer Network (2010) Practice Guidelines in Oncology v.1.2010. Myeloid Growth Factors. Available at: http://www.nccn.org/professionals/physician_gls/PDF/myeloid_growth.pdf. Accessed 2 Feb 2010
19. Greil R, Psenak O, Roila F (2008) Hematopoietic growth factors: ESMO recommendations for the applications. Ann Oncol 19 (Suppl 2):ii116–ii118
20. Carrato A, Paz-Ares Rodriguez L, Rodriguez Lescure A, Fernandez C, de Tejerina AM, Diaz Rubio Garcias E, Perez Segura P, Costenla Figueras M, Garcia Carbonero R, Gomez Cordina J, Lluch Hernandez A, Maroto Rey JP, Martin Jimenez M, Mayordomo Camara JI, Moreno Noguera JA, Rueda Dominguez A (2009) Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients. Clin Transl Oncol 11:446–454
21. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, Schiffer CA, Smith TJ, Somlo M, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Somerfield MR (2006) 2006 Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American society of clinical oncology growth factors expert panel. J Clin Oncol 18:3558–3585
22. Vogel CW, Wojtkiewicz MW, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, Neumann TA, Schwartzberg LS (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178–1184
23. Timmer-Bonte JN, de Boo TM, Smit HJ, Biesma B, Wilschut FA, Cheragwandii SA, Termeer A, Hensing CA, Akkermans J, Adang EM, Bootsma GP, Tjan-Heijnen VC (2005) Prevention of chemotherapy-induced febrile neutropenia by prophylactic anti-biotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study. J Clin Oncol 23:7974–7984
24. Ajani JA (2008) Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen. Cancer 113:945–955
25. Posner M, Vermorken JB (2008) Induction therapy in the modern era of combined-modality therapy for locally advanced head and neck cancer. Semin Oncol 35:221–228
26. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desauinou I, Bernier J, Lefebvre JL (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695–1704

27. Falco P, Cavallo F, Larocca A, Liberati AM, Musto P, Boccadoro M, Palumbo A (2008) Lenalidomide and its role in the management of multiple myeloma. Expert Rev Anticancer Ther 8:865–874

28. Palumbo A, Dimopoulos M, Miguel JS, Harousseau JL, Attal M, Hussein M, Knop S, Ludwig H, von Lilienfeld-Toal M, Sonneveld P (2009) Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Blood 23:87–93

29. Pal R, Roodman GD, Mapara M, Mocinski L, List AF, Lentzsch S (2008) Immunomodulatory derivatives of thalidomide (IMiD)-induced neutropenia is associated with PU1 downregulation and myeloid maturation arrest. Blood 112:Abstract 845

30. Repetto L, Bignanzi L, Koehne CH, Luebbe AS, Soubeyran P, Tjan-Heijnen VC, Aapro MS (2003) EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in myeloid maturation arrest. Blood 112:Abstract 845

31. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Huos E, Guevin R, Howell A, Forndater T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Collwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Lorett C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302–2313

32. Martin M, Lluch A, Segui MA, Ruiz A, Ramos M, Adrover E, Rodriguez-Lescure A, Grosse R, Calvo L, Fernandez-Chacon C, Roset M, Antón A, Isla D, del Prado PM, Iglesias L, Zaluzki J, Arcusa A, Lopez-Vega JM, Muñoz M, Mel JR (2006) Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 17:1205–1212

33. von Minckwitz G, Kümmel S, du Bois A, Eiermann W, Eidmann H, Gerber B, Hilfrich J, Huerer J, Costa SD, Jackisch C, Grasshoff ST, Vescia S, Skacel T, Loibl S, Mehta KM, Kaufmann M (2008) Pegfilgrastim +/– ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEAPARTIO study. Ann Oncol 19:292–298

34. Romieu G, Clemens M, Mahlberg R, Fargetot P, Constenla M, Schutte M, Easton V, Skacel T, Bacon PA, Brugger W (2007) Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial. Crit Rev Oncol Hematol 64:64–72

35. Balducci L, Al-Halawani H, Charu V, Tam J, Shahin S, Dreiling D, Vermorken JB, Remenar E, van Herpen C, Gorlia T, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L (2003) Elderly cancer patients receiving postoperative adjuvant treatment of non-Hodgkin’s lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. Br J Haematol 144:677–685

36. Sonneveld P (2009) Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Blood Rev 23:87–93

37. Aapro M, Schwenkglenks M, Lyman GH, Lopez Pousa A, Lawrinson S, Skacel T, et al (2010) Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy. Crit Rev Oncol Hematol (in press)

38. Crawford J, Dale DC, Kuderer NM, Culakova E, Poniewierski MS, Wolff D, Lyman GH (2008) Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw 6:109–118

39. Dranitsaris G, Rayson D, Vincent M, Chang J, Gelmon K, Sandor D, Reardon G (2008) Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model. Am J Clin Oncol 31:369–374

40. Jenkins P, Freeman S (2008) Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer. Ann Oncol 20:34–40

41. Culakova E, Wolff D, Poniewierski M, Crawford J, Dale D, Lyman G (2008) Factors related to neutropenic events in early stage breast cancer patients. J Clin Oncol 26(Suppl 15):Abstract 634

42. Shayne M, Crawford J, Dale DC, Culakova E, Lyman GH (2006) Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat 100:255–262

43. Ziepert M, Schmits R, Trumper L, Pfleunderschuh M, Loeffler M (2008) Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin’s lymphoma. Ann Oncol 19:752–762

44. Pettengell R, Bosly A, Szacs TD, Jackisch C, Leonard R, Paridaens R, Constenla M, Schwenglenks M (2009) Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. Br J Haematol 144:677–685

45. Lyman GH, Lyman CH, Agboola O (2005) Risk models for predicting chemotherapy-induced neutropenia. Oncologist 10:427–437

46. Lyman GH, Crawford J, Kuderer NM, Wolff D, Culakova E, Poniewierski MS, Dale DC (2008) Final risk prediction model for neutropenic complications in patients receiving cancer chemotherapy. Blood 112:Abstract 1312

47. Shaye M, Culakova E, Dale DC, Poniewierski MS, Wolff DA, Crawford J, Lyman H (2007) A validated risk model for early neutropenic events in older cancer patients receiving systemic chemotherapy. J Clin Oncol 25(Suppl 18):Abstract 9036

48. Norton L (1988) A Gompertzian model of human breast cancer growth. Cancer Res 48:7067–7071

49. Goldie JH, Coldman AJ (1979) A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727–1733

50. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martinogino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741.Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431–1439

51. Pfleunderschuh M, Trumper L, Kloor M, Schmits R, Feller AC, Rube C, Rudolph C, Reiser M, Hossfeld DK, Eiermacher H, Hasenclever D, Schmitz N, Loeffler M (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104:634–641

52. Pfleunderschuh M, Trumper L, Kloor M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D,
61. Piedbois P, Serin D, Priou F, Laplaige P, Greget S, Angellier E, Engert A, Bredenfeld H, Dohner H, Ho AD, Schmitz N, Berger Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Brusamolino E, Rusconi C, Montalbetti L, Gargantini L, Uziel L, Thatcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W, Wolf M, Bentley M, Marlton P, Horvath N, Lewis ID, Spencer II study. Haematologica 91:546
62. Wildiers H, Dirix L, Neven P, Prove A, Clement P, Squifflet P, Amant F, Skacel T, Paridaens R (2009) Delivery of adjuvant sequential dose-dense FEC-Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Res Treat 114:103–112
63. Kahan Z, Spanik S, Wagnerrova M, Skacel T, Planko B, Fitzthum E, Lindner E, Soldatenkova V, Zielinski CC, Brodowitz C (2008) Feasibility of two dose-dense FEC regimens with growth factor support for adjuvant therapy in patients with early breast cancer: results from a randomised study of the Central European Cooperative Oncology Group (CECOG). Breast Cancer Res Treat 112:557–563
64. Burstein HJ, Parker LM, Keshaviah A, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Boy, Come SE, Schumer ST, Bunnell CA, Haldoupis M, Gelman R, Winer EP (2005) Efficacy of pegfilgrastim and darbepoeitin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol 23:8340–8347
65. Pirker R, Ulserger E, Messner J, Aigner K, Forster B, Bacon P, Easton V, Skacel T (2006) Achieving full-dose, on-schedule administration of ACE chemotherapy every 14 days for the treatment of patients with extensive small-cell lung cancer. Lung 184:279–285
66. Trumper L, Zwick C, Ziepert M, Hohlko K, Schmits R, Mohren M, Liersch R, Bentz M, Greuven U, Wuck U, Hoffmann M, Metzner B, Hasenclever D, Loeffel M, Pfreundschuh M (2008) Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin’s lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens. Ann Oncol 19:538–544
67. Pfreundschuh M, Zwick C, Zeynalova S, Duhuren U, Pfluger KH, Vrielig T, Mesters R, Mergenthaler HG, Einsele H, Bentz M, Lengfelder E, Trümpel L, Rübe C, Schmitz N, Loeffel M (2008) Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin’s lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Ann Oncol 19:545–552
68. Earl HM, Hiller L, Dunn JA, Bathers S, Harvey P, Stanley A, Grieve RJ, Agrawal RK, Fernando IN, Brunt AM, McAdam K, O’Reilly S, Rea DW, Spooner D, Poole CJ (2008) NEAT: National Epirubicin Adjuvant Trial—toxicity, delivered dose intensity and quality of life. Br J Cancer 99:1226–1231
69. Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25:3158–3167
70. Sung L, Nathan PC, Aliababi SM, Tomlinson GA, Beye J (2007) Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 147:400–411
71. Bohlius J, Herbst C, Reiser M, Schwarzer G, Engert A (2008) Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev (4):CD003189. http://www.interscience.wiley.com/cochrane/clsyrev/articles/CD003189/frame.html
72. Dubois RW, Pinto LA, Bernal M, Badamgarav E, Lyman GH (2004) Benefits of GM-CSF versus placebo or G-CSF in reducing chemotherapy-induced complications: a systematic review of the literature. Supportive Cancer Ther 2(1):34–41
73. Lyman G, Kuderer N, Crawford J, Wolff D, Cukakova E, Poniewierski M, Dale DC (2008) Impact of pegfilgrastim on early all-cause mortality in patients receiving cancer chemotherapy. J Clin Oncol 26(Suppl 15):Abstract 6552
74. Yang BB, Kido A, Shibata A (2007) Serum pegfilgrastim concentrations during recovery of absolute neutrophil count in...
patients with cancer receiving pegfilgrastim after chemotherapy. Pharmacotherapy 27:1387–1393

75. Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, Lyman G (2007) Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin 23:2283–2295

76. Trillet-Lenoir V, Green J, Manegold C, Von Pawel J, Gatzeimeier U, Lebeau B, Depierre A, Johnson P, Decoster G, Tomita D et al (1993) Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319–324

77. Morrison VA, Wong M, Hershman D, Campos LT, Ding B, Malin J (2007) Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3–4 week chemotherapy regimens in community oncology practices. J Manag Care Pharm 13:337–348

78. Weycker D, Hackett J, Edelberg JS, Oster G, Glass AG (2006) Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 40:402–407

79. Scott SD, Chrischilles EA, Link BK, Delgado DJ, Fridman M, Stolshke BS (2003) Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin’s lymphoma treated with chemotherapy. J Manag Care Pharm 9(2 Suppl):15–21

80. von Minckwitz G, Schwenkglenks M, Skacel T, Lyman GH, Pousa AL, Bacon P, Easton V, Aapro MS (2009) Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropenia management: results from an integrated analysis. Eur J Cancer 45:608–617

81. Weycker D, Malin J, Kim J, Barron R, Edelberg J, Kartashov A, Oster G (2009) Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. Clin Ther 31:1069–1081

82. Del Giglio A, Eniu A, Ganea-Motan D, Topuzov E, Lubenau H (2008) XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC cancer 8:332

83. Mellstedt H, Niederwieser D, Ludwig H (2008) The challenge of biosimilars. Ann Oncol 19:411–419

84. Amsgen (2008) Neulasta Summary of Product Characteristics. Available at: http://www.ema.europa.eu/humandocs/PDFs/EPAR/neulasta/ema-combined-h420en.pdf. Accessed 2 Feb 2010

85. Amsgen (2009) Neupogen summary of product characteristics. http://emc.medicines.org.uk/medicine/7907/SPC/Neupogen +30MU+and+48MU+Vials+and+Singleject+-Syringes/. Accessed 2 Feb 2010

86. Holmes FA, Jones SE, O’Shaughnessy J, Vukelja S, George T, Savin M, Richards D, Glaspy J, Meza L, Cohen G, Dhami M, Budman DR, Hackett J, Brassard M, Yang BB, Liang BC (2002) Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women receiving docetaxel/doxorubicin. Cancer 98:2191–2198

87. Markman M (2003) Managing taxane toxicities. Support Care Cancer 11:144–147

88. Paba C, Sachdev J, Kronish L, Jahanzeb M, Waheed S (2008) Empiric dose reduction of pegfilgrastim in breast cancer patients receiving cytotoxic chemotherapy. J Clin Oncol 26(Suppl 15): Abstract 20636

89. Ip EJ, Lee-Ma A, Troxell LS, Chan J (2008) Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide. Am J Health Syst Pharm 65:1552–1555

90. Chugai Pharma (2009) Granocyte (lenograstim) Summary of product characteristics. http://emc.medicines.org.uk/emc/assets/ c/html/DisplayDoc.asp?DocumentID=8347. Accessed 2 Feb 2010

91. Holmes FA, O’Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, Neumann TA, Hill LR, Liang BC (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20:727–731

92. Yang BB, Hill R, Hollifield A, Green M, Holmes F, Sheridan W, Barnes RD (2003) Pegfilgrastim serum concentrations on the twelfth day after dosing are unlikely to stimulate granulopoiesis: a retrospective analysis of 6 clinical trials in a variety of cancer populations. Blood 102:Abstract 1918

93. Tysshler LB, Longton GM, Ellis GK, Livingston RB (1996) False positive tumor markers: elevation in patients with breast cancer on FAC-type chemotherapy and correlation with the development of hand-foot syndrome. Int J Biol Markers 11:203–206

94. Briasoilis E, Andreopoulou E, Tolis CF, Bliarrisoni E, Katsaraki A, Dimopoulos MA, Fountzilas G, Seferiades C, Pavlidis N (2001) G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting. Cancer 91:909–917

95. Pentheroudakis G, Malamou-Mitsu V, Briasoilis E, Damala K, Vassou A, Vartholomatos G, Kostakis N, Pavlidis N (2004) The neutrophil, not the tumor: serum CA 15-3 elevation as a result of granulocyte—colony stimulating factor-induced neutrophil M1C overexpression and neutrophilia in patients with breast carcinoma receiving adjuvant chemotherapy. Cancer 101:1767–1775

96. Saura C, Vilar E, Cortes J, Bellet M, Ocana A, Gomez P, Baselga J (2006) Pegfilgrastim induces elevation of serum of CA 15-3 in breast carcinoma patients after receiving dose-dense adjuvant chemotherapy. J Clin Oncol 24(Suppl 18):Abstract 8595

97. Hershman D, Neugut AI, Jacobson JS, Wang J, Tsai WY, McBride R, Bennett CL, Grann VR (2007) Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 99:196–205

98. Valagussa P, Moltierni A, Terenziani M, Zambetti M, Bona donna G (1994) Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer. Ann Oncol 5:803–808

99. Praga C, Bergh J, Bliss J, Bonnetriere J, Cesana B, Coombes RC, Fargeot P, Folin A, Fumoleau P, Giuliani R, Kerbrat P, Hery M, Nilsson J, Onida F, Piccart M, Shepherd L, Therasse P, Wils J, Rogers D (2005) Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 23:4179–4191

100. Patt DA, Duan Z, Fang S, Hortobagy GN, Giordano SH (2007) Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol 25:3871–3876

101. Clamp AR, Ryder WD, Bhattacharya S, Pettengell R, Radford JA (2008) Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin’s lymphoma. Br J Cancer 99:253–258

102. Lyman GH, Dale DC, Wolf J, Balukova E, Kuderer NM, Poniewierski MS, Crawford J (2008) Standard versus dose-intensified chemotherapy with granulocyte colony-stimulating factor for malignant lymphoma: evaluation of risk for acute myeloid leukemia or myelodysplastic syndrome. Blood 112: Abstract 2390
103. Touw IP, Bontenbal M (2007) Granulocyte colony-stimulating factor: key (f)actor or innocent bystander in the development of secondary myeloid malignancy? J Natl Cancer Inst 99:183–186

104. Viñolas N, Gúrpide A, Frau A, González Larriba J, Lamas M, Alvarez F, et al (2007) Clinical and economic impact of febrile neutropenia management of lung cancer patients in clinical practice in Spain (Abstract 6567). 14th European Cancer Conference; 23–27 September, Barcelona, Spain

105. Durand-Zaleski I, Vainchtock A, Bogillot O (2007) L’utilisation de la base nationale PMSI pour déterminer le coût d’un symptôme: le cas de la neutropénie fébrile. J Econ Med 25:269–280

106. Eldar-Lissai A, Cosler LE, Culakova E, Lyman GH (2008) Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health 11:172–179

107. Lyman G, Lalla A, Barron R, Dubois RW (2009) Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin’s lymphoma receiving CHOP-21 in United States. Curr Med Res Opin 25:401–411

108. Ramsey SD, Liu Z, Boer R, Sullivan SD, Malin J, Doan QV, Dubois RW, Lyman GH (2009) Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. Value Health 12:217–225